Published in Am J Med on December 01, 2001
Evidence-based clinical guidelines for immigrants and refugees. CMAJ (2010) 3.57
Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19
Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis (2013) 1.65
Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat (2010) 1.31
The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One (2014) 1.25
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One (2013) 1.14
Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One (2012) 1.03
Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations. BMJ Open (2016) 0.93
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction (2015) 0.92
Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? PLoS One (2013) 0.88
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Glob Public Health (2014) 0.84
Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. BMJ Open (2014) 0.84
Ending hepatitis C in the United States: the role of screening. Hepat Med (2014) 0.81
Cost-Effectiveness of HBV and HCV Screening Strategies - A Systematic Review of Existing Modelling Techniques. PLoS One (2015) 0.80
Is it time for mass screening for hepatitis C? Am J Med (2001) 0.75
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis (2001) 2.56
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.31
Mushroom poisoning--from diarrhea to liver transplantation. Am J Gastroenterol (2001) 1.93
Hepatitis C, interferon alfa, and depression. Hepatology (2000) 1.91
Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther (2012) 1.69
An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol (2000) 1.42
Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2010) 1.31
Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 1.17
Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol (2000) 1.14
Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther (2011) 1.12
Editorial: probiotics in NASH - more studies are needed. Aliment Pharmacol Ther (2014) 1.08
Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 1.07
Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 1.07
Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver (2001) 1.05
Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl (2001) 1.05
Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat (2011) 1.01
Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther (2009) 0.97
Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest (2001) 0.97
Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. Aliment Pharmacol Ther (2009) 0.97
Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology (1999) 0.94
Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol (2006) 0.93
Transjugular intrahepatic portosystemic shunts (TIPS): a decade later. J Clin Gastroenterol (2000) 0.92
Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat (2011) 0.91
Patent ductus venosus in an adult presenting as pulmonary hypertension, right-sided heart failure, and portosystemic encephalopathy. Am J Med (2001) 0.87
Health-related quality of life (HRQL) in chronic liver disease. Dig Liver Dis (2005) 0.84
Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C. J Viral Hepat (2010) 0.84
Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther (2014) 0.84
Hepatitis C virus RNA assays: a comparison of SuperQuant and Monitor. J Clin Gastroenterol (2001) 0.83
Survival and resource utilization in liver transplant recipients: the impact of admission to the intensive care unit. Transplant Proc (2003) 0.82
Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis (2015) 0.82
The metabolic syndrome and nonalcoholic fatty liver disease. Panminerva Med (2006) 0.81
The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis. Cleve Clin J Med (2000) 0.81
Study of host and virological factors of patients with chronic HCV infection and associated laboratory or clinical autoimmune manifestations. Clin Exp Rheumatol (2004) 0.80
Mortality associated with alcohol-related liver disease. Aliment Pharmacol Ther (2013) 0.78
Chronic liver disease and health-related quality of life. Gastroenterology (2001) 0.78
Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C). J Viral Hepat (2011) 0.78
Hepatitis C, cryoglobulinemia, and cutaneous vasculitis associated with unusual and serious manifestations. Am J Gastroenterol (2001) 0.78
Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation (2001) 0.77
Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply. Aliment Pharmacol Ther (2014) 0.75
Symptomatic porphyria cutanea tarda and B-immunoblastic lymphoma: is there an association? Am J Hematol (1996) 0.75
In diagnosing hepatitis C, which patient needs which test? Cleve Clin J Med (1999) 0.75
Viral hepatitis guide for practicing physicians. Cleveland Clinic of Medicine. Cleve Clin J Med (2000) 0.75
Treatment of Crigler-Najjar type II with small-dose phenobarbital. Dig Dis Sci (1995) 0.75